NICE wants more info on Norgine's rifaximin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has called on Norgine to provide more information on its drug rifaximin (known as Xifaxan or Targaxan) to treat a brain disease caused by liver failure.